Pharmaceuticals · 2023 · 14 citations · 44 references
MedicineImmunologyOncologyCancer ImmunologyChemotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyChemotherapy ResistanceCytotoxic ChemotherapyImmunotherapy For Breast CancerTumor Microenvironment ModulationBreast Cancer ChemotherapyHost-microbiome AssociationsMicrobiome-host InteractionsProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Cell Death Protein 1 CostimulationProgrammed Cell Death Protein 1 InhibitorsProgrammed Cell Death Protein 1 RegulationProgrammed Death-1 Blockade
Immunotherapy targeting program cell death protein 1 (PD-1) in addition to chemotherapy has improved the survival of triple-negative breast cancer (TNBC) patients. However, the development of resistance and toxicity remain significant problems. Using the translationally relevant 4T1 mouse model of TNBC, we report here that dietary administration of the phytochemical quercetin enhanced the antitumor action of Cyclophosphamide, a cytotoxic drug with significant immunogenic effects that is part of the combination chemotherapy used in TNBC. We observed that quercetin favorably modified the host fecal microbiome by enriching species such as Akkermansia muciniphilia, which has been shown to improve response to anti-PD-1 therapy. We also show that quercetin and, to a greater extent, Cyclophosphamide increased the systemic frequency of T cells and NK cells. In addition, Cyclophosphamide alone and in combination with quercetin reduced the frequency of Treg, which is consistent with an antitumor immune response. On the other hand, Cyclophosphamide did not significantly alter the host microbiome, suggesting complementarity between microbiome- and immune-mediated mechanisms in potentiating the antitumor action of Cyclophosphamide by quercetin. Overall, these results support the potential for microbiota-centered dietary intervention to overcome resistance to chemoimmunotherapy in TNBC.
44
DADA2: High-resolution sample inference from Illumina amplicon data
Benjamin J. Callahan, Paul J. McMurdie, Michael Rosen et al. · Nature Methods · 2016 · 36.3K citations
Metagenomic biomarker discovery and explanation
Nicola Segata, Jacques Izard, Levi Waldron et al. · Genome biology · 2011 · 16.7K citations · Full text
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa et al. · Science · 2017 · 5.4K citations
Life Sciences, Immunology, Oncology +17
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2017 · 5.4K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +17